<DOC>
	<DOCNO>NCT01039181</DOCNO>
	<brief_summary>Cholangiocarcinoma ( CCA ) , cancer bile duct , first cause cancer death people northeast Thailand . The incidence CCA region high country world . CCA slow grow highly metastatic tumor . At present , standard chemotherapy effective treatment CCA . Most patient short survival diagnosis . Strong evidence vitro , animal clinical study indicate vitamin D prevent control growth cancer . Our preclinical study CCA cell line , animal patient tissue culture indicate vitamin D effectively reduce growth CCA . Supplementation vitamin D chemotherapeutic drug enhance drug toxicity well response . At present , several clinical trial USA supplementation vitamin D analog cancer patient . The side effect toxicity use vitamin D supplementation low , patient stable disease good response . The current study set clinical trial phase II vitamin D ( calcitriol ) combination 5-fluorouracil , Mitomycin C Leucovorin open label-non-randomized study evaluate tumor response patient advance intrahepatic cholangiocarcinoma . This study provide alternative/effective chemotherapy treatment CCA patient . Better survival improve quality life also expect .</brief_summary>
	<brief_title>Calcitriol Advanced Intrahepatic Cholangiocarcinoma</brief_title>
	<detailed_description>- OUTLINE : This dose-limiting toxicity study calcitriol . - EVALUAITON : During initial phase , 14 patient accrue study . If number patient 's response calcitriol 5-fluorouracil/mitomycin C/leucovorin less 1/14 , study stop . However one patient responses calcitriol 5-fluorouracil/mitomycin C/leucovorin , new 14 patient accrue secondary phase study .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<criteria>1 . Proven histological cytological diagnosis advance intrahepatic cholangiocarcinoma ( stage III , IV ) ; Patients ineligible surgery . 2 . Patients must measurable evaluable disease . 3 . Age 3065 year 4 . Performance status must ECOG 01 . 5 . No prior use chemotherapy palliative radiation 6 . Tumor size CT scan must large 10 mm.x10 mm . 7 . Life expectancy least 12 week . 8 . Adequate bone marrow , hepatic , renal function , evidence following : WBC &gt; 3.0 x 109/L , neutrophil &gt; 1.5 x 109 /L ; platelet count &gt; 100 x 109/L ; Hct &gt; 30 % ; total bilirubin &lt; 1 mg/dL ; Liver enzymes ( alkaline phosphatase , AST , ALT ) &lt; 3 time upper limit normal range . Creatinine within normal range . 9 . Female patient must pregnant ; must postmenopausal practice accepted form birth control . If pregnancy possibility , pregnancy test require prior initiation therapy . 10 . Patients must accessible treatment followup . 11 . Patient investigator sign studyspecific consent form , indicate investigational nature study . 1 . Known hypersensitivity Vitamin D , 5fluorouracil , mitomycin C 2 . Hypercalcemia ( patient correct serum calcium &gt; 10.5 mg/dL ) hyperparathyroid 3 . History renal/bladder stone 4 . History nephrectomy 5 . 30 day prior study entry , CT scan ultrasound show renal/bladder stone . 6 . Patients congestive heart failure arrhythmia unstable angina within 6 month prior study 7 . Pregnancy/Lactation 8 . Palliative radiation adjuvant therapy chemotherapy tumor area 9 . No concurrent malignancy 10 . No active infection 11 . Metastasis central nervous system 12 . Metastasis Bone 13 . Renal insufficiency ( creatinine &gt; 1.5 mg/dL ) 14 . Patients concurrent cancer clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Calcitriol</keyword>
	<keyword>cholangiocarcinoma</keyword>
	<keyword>Clinical trial</keyword>
</DOC>